Manufactures oral-film medicines for pharmaceutical licensees and develops epinephrine product candidates for people with severe allergic reactions.
10-K for FY2025, filed Mar 4, 2026Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and…View ↗
We are presently the worldwide leader in oral film drug delivery and manufacturing, having historically supplied the substantial majority…View ↗
Anaphylm® (dibutepinephrine) sublingual film – the first and only non-device based, orally delivered epinephrine prodrug product candidate…View ↗
We manufacture based on receipt of purchase orders from our licensees, and our licensees have an obligation to accept these orders once…View ↗
Pharmaceutical licensees pay for made-to-order products after quality checks; the company also earns royalties on licensees’ sales, fees for contracted development work as tasks or milestones are completed, and license payments when rights transfer or over the license term. It sells its own products when they ship.
10-K for FY2025, filed Mar 4, 2026We manufacture based on receipt of purchase orders from our licensees, and our licensees have an obligation to accept these orders once…View ↗
We realize revenue from licenses of our intellectual property. For licenses that do not require further development or other ongoing…View ↗
Co-development and research fees are earned through performance of specific tasks, activities or completion of stages of development…View ↗
This net revenue is recognized when product is shipped and title passes to the customer, typically at time of delivery. At the time of…View ↗
$44.5M
10-K for FY2025, filed Mar 4, 2026
$44.5M ↗
Pharmaceutical licensees order made-to-order products directly and handle marketing and sales themselves; other pharmaceutical companies contract for development work and intellectual-property licenses.
10-K for FY2025, filed Mar 4, 2026We manufacture based on receipt of purchase orders from our licensees, and our licensees have an obligation to accept these orders once…View ↗
We realize revenue from licenses of our intellectual property. For licenses that do not require further development or other ongoing…View ↗
Co-development and research fees are earned through performance of specific tasks, activities or completion of stages of development…View ↗
10-K for FY2025, filed Mar 4, 2026
Customers are considered major customers when net revenue exceeds 10% of total revenue for the period or outstanding receivable balances…View ↗
No. It lost $83.8M in FY2025.
10-Q for Q3 FY2026, filed Nov 3, 2026
−$16.5MView ↗
8-K, filed Oct 14, 2026
On October 13, 2026, Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") entered into a license agreement (the "License Agreement")…View ↗
Shrinking. Revenue fell 12% in 4 years, from $50.8M in FY2021 to $44.5M in FY2025, about 3% a year.
Epinephrine delivery
The older report described an epinephrine prodrug in sublingual film form; the latest describes a topical gel candidate.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 4, 2026Our AdrenaVerse™ platform contains a library of over twenty epinephrine prodrug product candidates intended to control absorption and…View ↗
Competes with Teva, Viatris, Amneal Pharmaceuticals, Kaleo, U.S. Worldmeds, and ARS Pharmaceuticals
10-K for FY2025, filed Mar 4, 2026We expect that, if approved by the FDA, Anaphylm would compete with several existing products and other product candidates that target Type…View ↗
Loading...